Want to join the conversation?
On Sept. 9, 2015, $BIIB announced an agreement with Mitsubishi Tanabe Pharma Corp. (MTPC) to exclusively license MT-1303, a late stage experimental medicine with potential in multiple autoimmune indications. Under the terms of the agreement, $BIIB will receive worldwide rights to MT-1303, excluding Asia.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.